Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01488513 · ClinicalTrials.gov registry record · Phase 1
ABC294640 in Treating Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by RedHill Biopharma Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT01488513: Completed Phase 1 study, sponsored by RedHill Biopharma Limited.
NCT01488513 is a Phase 1 study that has completed, run by RedHill Biopharma Limited. The registered enrollment target is 22 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01488513, a Phase 1 study, has completed, sponsored by RedHill Biopharma Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of ABC294640 in treating patients with advanced solid tumors. ABC294640 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Please note that the FDA OOPD is participating as a funding source.
Primary Outcome
MTD defined as the highest dose at which 0 or 1 patient of 6 experiences a DLT. The DLT rate will be estimated with its 95% confidence interval.
Interventions
- DRUG sphingosine kinase-2 inhibitor ABC294640
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2011-08 |
| Est. Completion | 2015-07 |
| Phase | Phase 1 |
What the finished NCT01488513 record still lists
NCT01488513 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% lower).
The record links to 0 conditions, and to 1 intervention - of which sphingosine kinase-2 inhibitor ABC294640 is the first listed.
NCT01488513 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01488513 about?
NCT01488513 is a clinical study titled "ABC294640 in Treating Patients With Advanced Solid Tumors". This phase I trial studies the side effects and best dose of ABC294640 in treating patients with advanced solid tumors. ABC294640 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Please note that the FDA OOPD is participating as a funding source.
What is the current status of trial NCT01488513?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2011-08. Estimated completion is 2015-07.
What interventions are being tested in trial NCT01488513?
The interventions under investigation include: sphingosine kinase-2 inhibitor ABC294640 (DRUG).
Who is sponsoring clinical trial NCT01488513?
This trial is sponsored by RedHill Biopharma Limited, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01488513's enrollment target sits among peer trials
22 1601st of 2000 higher than 386 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia